Skip to main content
Caplight Logo









Incendia Therapeutics

Incendia Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.incendiatx.com/

Last Round

Convertible Debt

Apr 18, 2024

Total Funding Raised

$67.31M

Company Overview

Incendia Therapeutics is a biotechnology company that develops innovative anti-cancer therapies designed to reprogram the tumor microenvironment to enhance treatment efficacy.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

precision oncologytumor microenvironmentimmuno-oncologycancer immunotherapybiotech startupdrug discoverybiopharmadrug pipelinedigital pathologycold tumor therapybiomarker discoverytranslational medicineclinical-stage biotechAI in drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Incendia Therapeutics Comparables

Compare Incendia Therapeutics with similar companies based on industry and business-model similarity.

Incendia Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Alixia
87%
ImmunoGenesis
83%
Sonata Therapeutics
83%

Incendia Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Convertible DebtApr 18, 2024
Series ANov 3, 2021

Key People

Founding team and executive leadership

Wendye Robbins

President And Chief Executive Officer

Executive Team

Incendia Therapeutics Investors

Notable investors and investment history

Incendia Therapeutics investors
InvestorRounds
S32Series A
Creacion VenturesSeries A
abrdn Inc.Convertible Debt
Taiho VenturesSeries A
Northpond VenturesSeries A
Tekla Capital ManagementSeries A
Breakout VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 3, 2021

    $65M round led by Pfizer Ventures and Taiho Ventures.

Incendia Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Incendia Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Incendia Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range24
Year Founded2019
Last FundingApr 18, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?